Nektar Therapeutics

Yahoo Finance • 8 days ago

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as... Full story

Yahoo Finance • 17 days ago

Nektar eyes late-stage program for eczema therapy after positive mid-stage data

[Atopic Dermatitis on the diagnosis list, medical concept] Michail_Petrov-96 Nektar Therapeutics (NKTR [https://seekingalpha.com/symbol/NKTR]) added ~24% in the premarket on Tuesday after the company announced that, following positive mid... Full story

Yahoo Finance • 2 months ago

Wall Street Futures Decline Premarket Tuesday Pending Key US Economic Data, Delayed Jobs Report

Wall Street futures were declining premarket Tuesday pending the release of key US economic data, in PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Deutsche Bank upgraded Autodesk (ADSK)... Full story

Yahoo Finance • 4 months ago

Nektar outlines $1B market opportunity for REZPEG in alopecia areata as Phase III plans advance

Earnings Call Insights: Nektar Therapeutics (NKTR) Q3 2025 MANAGEMENT VIEW * CEO Howard W. Robin welcomed Dr. Mary Tagliaferri back as Chief Medical Officer, noting her previous role in the successful Phase II program in atopic dermati... Full story

Yahoo Finance • 4 months ago

Nektar Therapeutics Non-GAAP EPS of $1.85 beats by $4.64, revenue of $11.79M beats by $1.59M

* Nektar Therapeutics press release [https://seekingalpha.com/pr/20298070-nektar-therapeutics-reports-third-quarter-2025-financial-results] (NKTR [https://seekingalpha.com/symbol/NKTR]): Q3 Non-GAAP EPS of $1.85 beats by $4.64. * Reven... Full story

Yahoo Finance • 5 months ago

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

Key Points Shares of Nektar Therapeutics and Mineralys Therapeutics have risen sharply, and could run even further. Nektar is developing an experimental eczema treatment. Millions of patients with stubbornly high blood pressure could bene... Full story

Yahoo Finance • 8 months ago

Why Nektar Therapeutics Stock Dived by 3% Today

Key Points The company announced it closed its latest capital-raising effort. This took the form of a nearly 5-million strong, secondary share issue. Nektar Therapeutics(NASDAQ: NKTR) saw its stock price erode on Thursday, following the... Full story

Yahoo Finance • 8 months ago

Top Midday Decliners

Nektar Therapeutics (NKTR) slid 4.5% on Thursday after the biopharmaceuticals firm overnight said it PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 months ago

Nektar Therapeutics stock dips after pricing $100M stock offering

* Nektar Therapeutics (NASDAQ:NKTR [https://seekingalpha.com/symbol/NKTR]) shares slipped over 3% premarket on Tuesday after the biotechnology company priced a stock offering to raise around $100M. * Nektar is selling 4.25M shares of c... Full story

Yahoo Finance • 8 months ago

Catalyst Watch: Jobs Report, Tesla deliveries, Constellation Brands earnings, and Circle ratings

[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • 8 months ago

Nektar Therapeutics surge continues as stock up another 25%

[graph from neons 1] Jonathan Kitchen * Nektar Therapeutics (NASDAQ:NKTR [https://seekingalpha.com/symbol/NKTR]), which closed Tuesday up ~156% after its lead asset, rezpegaldesleukin, met its main goal in a mid-stage trial for atopic d... Full story

Yahoo Finance • 8 months ago

Nvidia and Tesla Stir Mega-Cap Movers on Wednesday's Market

Wednesday’s market has seen notable fluctuations among stocks, with significant movements in both the mega-cap and large-cap categories. Nvidia Corp (NASDAQ:NVDA) has experienced a surge, while Tesla Motors (NASDAQ:TSLA) has dipped. Ot... Full story

Yahoo Finance • 8 months ago

Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares. The company this morning announced positive results from the induction period of its ongoing Phase 2... Full story

Yahoo Finance • 8 months ago

Nektar stock price target raised to $69 from $2 at Jefferies on AD data

Investing.com - Jefferies raised its price target on Nektar Therapeutics (NASDAQ:NKTR) to $69.00 from $2.00 on Tuesday, maintaining a Buy rating following positive Phase 2b atopic dermatitis (AD) data for the company’s Rezpeg treatment.... Full story

Yahoo Finance • 8 months ago

Nektar stock price target raised to $100 from $60 at BTIG on trial data

Investing.com - BTIG raised its price target on Nektar Therapeutics (NASDAQ:NKTR) to $100 from $60 while maintaining a Buy rating following positive Phase 2b trial results for the company’s atopic dermatitis treatment. The research firm... Full story

Yahoo Finance • 8 months ago

Nektar's rezpegaldesleukin shows positive results in atopic dermatitis trial

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a biotechnology company with a market capitalization of $118 million, announced Tuesday that its Phase 2b REZOLVE-AD study of rezpegaldesleukin met its primary endpoint in patients with mo... Full story

Yahoo Finance • 8 months ago

Nektar Therapeutics stock soars on upcoming atopic dermatitis data

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic dermatitis treatment in June 2025. The cl... Full story

Yahoo Finance • 11 months ago

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling b... Full story

Yahoo Finance • 11 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference:(... Full story